Tiludronate and Clodronate do not Affect Bone Structure or Remodeling Kinetics over a 60 Day Randomized Trial - Dataset

Tiludronate (TIL) and clodronate (CLO) are FDA-approved bisphosphonate
drug therapies for navicular disease in horses. Although clinical
studies have determined their ability to reduce lameness in horses, data
regarding the effect on bone structure and remodeling is lacking.
Additionally, due to off-label use of these drugs in young performance
horses, effects on bone in young horses need to be investigated.
Therefore, the purpose of this randomized, experimental pilot study was
to determine the effect of TIL and CLO on normal bone cells, structure
and remodeling after 60 days in clinically normal, young horses.
Additionally, the effect of CLO on bone healing 60 days after an induced
defect was investigated. Data included are raw micro-computed
tomography data, and static and dynamic histomorphometry data from all
horses analyzed. Abbreviations, formulas, and units are standard for the
field and are referenced within the published article.